Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 214

1.

Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma.

Lolli C, Medri M, Ricci M, Schepisi G, Filograna A, De Giorgi U, Stanganelli I.

Medicine (Baltimore). 2018 Dec;97(52):e13810. doi: 10.1097/MD.0000000000013810.

2.

Oxaliplatin plus leucovorin and 5-fluorouracil (FOLFOX-4) as a salvage chemotherapy in heavily-pretreated platinum-resistant ovarian cancer.

Conteduca V, Gurioli G, Rossi L, Scarpi E, Lolli C, Schepisi G, Farolfi A, De Lisi D, Gallà V, Burgio SL, Menna C, Amadori A, Losi L, Amadori D, Costi MP, De Giorgi U.

BMC Cancer. 2018 Dec 19;18(1):1267. doi: 10.1186/s12885-018-5180-1.

3.

[Influenza vaccination in advanced cancer patients undergoing immunotherapy with anti-PD-1/PD-L1 immune checkpoint inhibitors: what data do we have for the clinical recommendation?]

Bersanelli M, Buti S, De Giorgi U, Di Maio M, Giannarelli D, Banna GL.

Recenti Prog Med. 2018 Nov;109(11):540-546. doi: 10.1701/3031.30291. Italian.

PMID:
30565573
4.

Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database.

Del Bene G, Calabrò F, Giannarelli D, Plimack ER, Harshman LC, Yu EY, Crabb SJ, Pal SK, Alva AS, Powles T, De Giorgi U, Agarwal N, Bamias A, Ladoire S, Necchi A, Vaishampayan UN, Niegisch G, Bellmunt J, Baniel J, Galsky MD, Sternberg CN.

Front Oncol. 2018 Nov 19;8:463. doi: 10.3389/fonc.2018.00463. eCollection 2018.

5.

Safety and Efficacy of Pazopanib in First-Line Metastatic Renal-Cell Carcinoma With or Without Renal Failure: CORE-URO-01 Study.

Masini C, Vitale MG, Maruzzo M, Procopio G, de Giorgi U, Buti S, Rossetti S, Iacovelli R, Atzori F, Cosmai L, Vignani F, Prati G, Scagliarini S, Guida A, Berselli A, Pinto C.

Clin Genitourin Cancer. 2019 Feb;17(1):e150-e155. doi: 10.1016/j.clgc.2018.10.001. Epub 2018 Oct 10.

PMID:
30396828
6.

Plasma androgen receptor and serum chromogranin A in advanced prostate cancer.

Conteduca V, Scarpi E, Salvi S, Casadio V, Lolli C, Gurioli G, Schepisi G, Wetterskog D, Farolfi A, Menna C, De Lisi D, Burgio SL, Beltran H, Attard G, De Giorgi U.

Sci Rep. 2018 Oct 18;8(1):15442. doi: 10.1038/s41598-018-33774-4.

7.

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.

Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S.

Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080.

PMID:
30326787
8.

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry.

Cathomas R, Klingbiel D, Bernard B, Lorch A, Garcia Del Muro X, Morelli F, De Giorgi U, Fedyanin M, Oing C, Haugnes HS, Hentrich M, Fankhauser C, Gillessen S, Beyer J.

J Clin Oncol. 2018 Oct 4:JCO1800210. doi: 10.1200/JCO.18.00210. [Epub ahead of print]

9.

Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma.

Santoni M, Piva F, De Giorgi U, Mosca A, Basso U, Santini D, Buti S, Lolli C, Terrone C, Maruzzo M, Iuliani M, Bersanelli M, Conti A, Mazzucchelli R, Montironi R, Burattini L, Berardi R.

Anticancer Res. 2018 Oct;38(10):5773-5782. doi: 10.21873/anticanres.12916.

PMID:
30275199
10.

Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.

Maines F, De Giorgi U, Procopio G, Facchini G, Fratino L, Sabbatini R, Gasparro D, Basso U, Mosillo C, Campadelli E, Massari F, Sava T, Sirotova S, Messina C, Scagliarini S, Conteduca V, Verzoni E, Rossetti S, Veccia A, Kinspergher S, Caffo O.

Future Oncol. 2018 Nov;14(26):2691-2699. doi: 10.2217/fon-2018-0113. Epub 2018 Sep 12.

PMID:
30207488
11.

Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program.

Prisciandaro M, Ratta R, Massari F, Fornarini G, Caponnetto S, Iacovelli R, De Giorgi U, Facchini G, Scagliarini S, Sabbatini R, Caserta C, Peverelli G, Mennitto A, Verzoni E, Procopio G.

Am J Clin Oncol. 2019 Jan;42(1):42-45. doi: 10.1097/COC.0000000000000478.

PMID:
30204614
12.

68Ga-PSMA-PET: added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer.

Malaspina S, De Giorgi U, Kemppainen J, Del Sole A, Paganelli G.

Radiol Med. 2018 Dec;123(12):952-965. doi: 10.1007/s11547-018-0929-9. Epub 2018 Aug 16. Review.

PMID:
30116970
13.

Long-term Response to First-line Pazopanib Therapy in mRCC Patients: A Multicenter Italian Experience.

Sbrana A, Biasco E, Paolieri F, Palesandro E, Caserta C, Iacovelli R, Detti B, Santini D, Mosca A, Morelli F, Fornarini G, De Giorgi U, Masini C, Galli L.

Anticancer Res. 2018 Aug;38(8):4913-4918. doi: 10.21873/anticanres.12807.

PMID:
30061269
14.

Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.

de Bono JS, De Giorgi U, Rodrigues DN, Massard C, Bracarda S, Font A, Arranz Arija JA, Shih KC, Radavoi GD, Xu N, Chan WY, Ma H, Gendreau S, Riisnaes R, Patel PH, Maslyar DJ, Jinga V.

Clin Cancer Res. 2019 Feb 1;25(3):928-936. doi: 10.1158/1078-0432.CCR-18-0981. Epub 2018 Jul 23.

PMID:
30037818
15.

Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.

De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group.

BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23.

PMID:
29956884
16.

Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24).

Farolfi A, Petrone M, Scarpi E, Gallà V, Greco F, Casanova C, Longo L, Cormio G, Orditura M, Bologna A, Zavallone L, Ventriglia J, Franzese E, Loizzi V, Giardina D, Pigozzi E, Cioffi R, Pignata S, Giorda G, De Giorgi U.

Target Oncol. 2018 Aug;13(4):469-479. doi: 10.1007/s11523-018-0574-1.

PMID:
29948780
17.

68Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients.

Caroli P, Sandler I, Matteucci F, De Giorgi U, Uccelli L, Celli M, Foca F, Barone D, Romeo A, Sarnelli A, Paganelli G.

Eur J Nucl Med Mol Imaging. 2018 Jun 19. doi: 10.1007/s00259-018-4067-3. [Epub ahead of print]

PMID:
29922948
18.

Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.

Pal SK, Rosenberg JE, Hoffman-Censits JH, Berger R, Quinn DI, Galsky MD, Wolf J, Dittrich C, Keam B, Delord JP, Schellens JHM, Gravis G, Medioni J, Maroto P, Sriuranpong V, Charoentum C, Burris HA, Grünwald V, Petrylak D, Vaishampayan U, Gez E, De Giorgi U, Lee JL, Voortman J, Gupta S, Sharma S, Mortazavi A, Vaughn DJ, Isaacs R, Parker K, Chen X, Yu K, Porter D, Graus Porta D, Bajorin DF.

Cancer Discov. 2018 Jul;8(7):812-821. doi: 10.1158/2159-8290.CD-18-0229. Epub 2018 May 30.

PMID:
29848605
19.

The outcome to axitinib or everolimus after sunitinib in metastatic renal cell carcinoma.

Iacovelli R, Cossu Rocca M, Galli L, Sabbatini R, De Giorgi U, Santini D, Facchini G, Mosca A, Atzori F, Zucali P, Fornarini G, Massari F, Buti S, Ricotta R, Masini C, Toscani I, Biasco E, Guida A, Lolli C, De Lisi D, Rossetti S, Terrone C, Scartozzi M, Miggiano C, Pastorino A, Bersanelli M, Carlo-Stella G, Pinto C, Nobili E, Nolè F, Tortora G, Porta C.

Anticancer Drugs. 2018 Aug;29(7):705-709. doi: 10.1097/CAD.0000000000000632.

PMID:
29846246
20.
21.

Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?

Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C.

Clin Genitourin Cancer. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7.

PMID:
29803346
22.

Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.

Bracarda S, Galli L, Maruzzo M, Lo Re G, Buti S, Favaretto A, Di Costanzo F, Sacco C, Merlano M, Mucciarini C, Zafarana E, Romito S, Maestri A, Giorgio CG, Ionta MT, Turci D, De Giorgi U, Procopio G, Cortesi E, Giannarelli D, Porta C.

Future Oncol. 2018 Jun;14(14):1347-1354. doi: 10.2217/fon-2017-0570. Epub 2018 May 18.

PMID:
29774766
23.

Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.

Procopio G, Prisciandaro M, Iacovelli R, Cortesi E, Fornarini G, Facchini G, Cartenì G, Sabbatini R, Del Bene G, Galli L, Caserta C, Multari AG, Bregni M, Massari F, Buti S, De Giorgi U, Zustovich F, Milella M, Calabrò F, Mancini ML, Tortora G, Vernieri C, Santini D, Sorarù M, Ricotta R, Masini C, Tucci M, Fedeli SL, Ortega C, Mecozzi A, Ratta R, Sternberg CN, Verzoni E.

Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.

PMID:
29753637
24.

[177Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?

Paganelli G, De Giorgi U.

Lancet Oncol. 2018 Jun;19(6):725-726. doi: 10.1016/S1470-2045(18)30268-7. Epub 2018 May 8. No abstract available.

PMID:
29752181
25.

Reply to the letter to the editor 'Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer' by Yang et al.

Conteduca V, De Giorgi U, Lauletta G.

Ann Oncol. 2018 Aug 1;29(8):1879-1880. doi: 10.1093/annonc/mdy176. No abstract available.

PMID:
29750418
26.

Immune-Related Concepts in Biology and Treatment of Germ-Cell Tumors.

Chovanec M, De Giorgi U, Mego M.

Adv Urol. 2018 Mar 13;2018:3718165. doi: 10.1155/2018/3718165. eCollection 2018. Review.

27.

Laparoscopic surgery in the treatment of stage I adult granulosa cells tumors of the ovary: Results from the MITO-9 study.

Bergamini A, Ferrandina G, Candiani M, Cormio G, Giorda G, Lauria R, Perrone AM, Scarfone G, Breda E, Savarese A, Frigerio L, Gadducci A, Mascilini F, Maneschi F, Cassani C, Marchetti C, Cecere SC, Biglia N, De Giorgi U, Raspagliesi F, Lorusso D, Mangili G.

Eur J Surg Oncol. 2018 Jun;44(6):766-770. doi: 10.1016/j.ejso.2018.03.001. Epub 2018 Mar 10.

PMID:
29576462
28.

Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?

De Lisi D, De Giorgi U, Lolli C, Schepisi G, Conteduca V, Menna C, Tonini G, Santini D, Farolfi A.

Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):461-467. doi: 10.1080/17425255.2018.1455826. Epub 2018 Mar 23. Review.

PMID:
29557694
29.

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis.

Bravaccini S, Puccetti M, Bocchini M, Ravaioli S, Celli M, Scarpi E, De Giorgi U, Tumedei MM, Raulli G, Cardinale L, Paganelli G.

Sci Rep. 2018 Mar 9;8(1):4254. doi: 10.1038/s41598-018-22594-1.

30.

Systemic immune-inflammation index in germ-cell tumours.

Chovanec M, Cierna Z, Miskovska V, Machalekova K, Kalavska K, Rejlekova K, Svetlovska D, Macak D, Spanik S, Kajo K, Babal P, De Giorgi U, Mego M, Mardiak J.

Br J Cancer. 2018 Mar 20;118(6):831-838. doi: 10.1038/bjc.2017.460. Epub 2018 Feb 27.

PMID:
29485980
31.

Association among metabolic syndrome, inflammation, and survival in prostate cancer.

Conteduca V, Caffo O, Galli L, Maugeri A, Scarpi E, Maines F, Chiuri VE, Lolli C, Kinspergher S, Schepisi G, Santoni M, Santini D, Fratino L, Burgio SL, Salvi S, Menna C, De Giorgi U.

Urol Oncol. 2018 May;36(5):240.e1-240.e11. doi: 10.1016/j.urolonc.2018.01.007. Epub 2018 Mar 2.

PMID:
29402534
32.

Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications.

Kalavska K, Conteduca V, De Giorgi U, Mego M.

Curr Cancer Drug Targets. 2018;18(10):967-978. doi: 10.2174/1568009618666180102103959.

PMID:
29295694
33.

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

Powles T, Durán I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, Oudard S, Retz MM, Castellano D, Bamias A, Fléchon A, Gravis G, Hussain S, Takano T, Leng N, Kadel EE 3rd, Banchereau R, Hegde PS, Mariathasan S, Cui N, Shen X, Derleth CL, Green MC, Ravaud A.

Lancet. 2018 Feb 24;391(10122):748-757. doi: 10.1016/S0140-6736(17)33297-X. Epub 2017 Dec 18. Erratum in: Lancet. 2018 Oct 20;392(10156):1402.

PMID:
29268948
34.

Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.

Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G, Tonini G.

Oncotarget. 2017 Aug 7;8(59):100708-100716. doi: 10.18632/oncotarget.20022. eCollection 2017 Nov 21.

35.

Immunotherapy for Prostate Cancer: Where We Are Headed.

Schepisi G, Farolfi A, Conteduca V, Martignano F, De Lisi D, Ravaglia G, Rossi L, Menna C, Bellia SR, Barone D, Gunelli R, De Giorgi U.

Int J Mol Sci. 2017 Dec 5;18(12). pii: E2627. doi: 10.3390/ijms18122627. Review.

36.

TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.

Verzoni E, Ratta R, Grassi P, Salvioni R, Stagni S, Montone R, Fucà G, Cappelletti V, Reduzzi C, De Giorgi U, Procopio G.

Tumori. 2018 Oct;104(5):401-405. doi: 10.5301/tj.5000699. Epub 2018 May 9.

PMID:
29192741
37.

AR Copy Number and AR Signaling-directed Therapies in Castrationresistant Prostate Cancer.

Salvi S, Conteduca V, Lolli C, Testoni S, Casadio V, Zaccheroni A, Rossi L, Burgio SL, Menna C, Schepisi G, De Giorgi U.

Curr Cancer Drug Targets. 2018;18(9):869-876. doi: 10.2174/1568009617666171122145852.

PMID:
29173173
38.

Circulating androgen receptor combined with 18F-fluorocholine PET/CT metabolic activity and outcome to androgen receptor signalling-directed therapies in castration-resistant prostate cancer.

Conteduca V, Scarpi E, Caroli P, Salvi S, Lolli C, Burgio SL, Menna C, Schepisi G, Testoni S, Gurioli G, Paganelli G, Casadio V, Matteucci F, De Giorgi U.

Sci Rep. 2017 Nov 14;7(1):15541. doi: 10.1038/s41598-017-15928-y.

39.

Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.

Caroli P, De Giorgi U, Scarpi E, Fantini L, Moretti A, Galassi R, Celli M, Conteduca V, Rossi L, Bianchi E, Paganelli G, Matteucci F.

Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):348-354. doi: 10.1007/s00259-017-3866-2. Epub 2017 Nov 6.

PMID:
29110067
40.

Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong YN, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, Niegisch G, Necchi A, Sternberg CN, Srinivas S, Alva A, Vaishampayan U, Cerbone L, Liontos M, Rosenberg J, Powles T, Bellmunt J, Galsky MD; RISC Investigators.

Ann Oncol. 2018 Feb 1;29(2):361-369. doi: 10.1093/annonc/mdx692.

PMID:
29077785
41.

Consider Quality of Life to Improve Quality of Cancer Guidelines.

Schepisi G, Banna GL, De Giorgi U.

JAMA Intern Med. 2017 Oct 1;177(10):1537. doi: 10.1001/jamainternmed.2017.3694. No abstract available.

PMID:
28973270
42.

Venous Thromboembolism Risk in Patients With Locoregional Urothelial Tract Tumors.

Ramos JD, Wingate JT, Gulati R, Plimack ER, Harshman LC, Powles T, Crabb SJ, Niegisch G, Bellmunt J, Ladoire S, De Giorgi U, Hussain S, Alva AS, Baniel J, Agarwal N, Rosenberg JE, Vaishampayan UN, Galsky MD, Yu EY; RISC Investigators.

Clin Genitourin Cancer. 2017 Aug 24. pii: S1558-7673(17)30242-2. doi: 10.1016/j.clgc.2017.08.001. [Epub ahead of print]

PMID:
28923700
43.

Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Boustani J, Bertaut A, Galsky MD, Rosenberg JE, Bellmunt J, Powles T, Recine F, Harshman LC, Chowdhury S, Niegisch G, Yu EY, Pal SK, De Giorgi U, Crabb SJ, Caubet M, Balssa L, Milowsky MI, Ladoire S, Créhange G; Retrospective International Study of Cancers of the Urothelial Tract (RISC) Investigators.

Acta Oncol. 2018 Apr;57(4):491-497. doi: 10.1080/0284186X.2017.1369565. Epub 2017 Aug 30.

PMID:
28853615
44.

Urinary RNA-based biomarkers for prostate cancer detection.

Martignano F, Rossi L, Maugeri A, Gallà V, Conteduca V, De Giorgi U, Casadio V, Schepisi G.

Clin Chim Acta. 2017 Oct;473:96-105. doi: 10.1016/j.cca.2017.08.009. Epub 2017 Aug 12. Review.

PMID:
28807541
45.

Reduction of 68Ga-PSMA renal uptake with mannitol infusion: preliminary results.

Matteucci F, Mezzenga E, Caroli P, Di Iorio V, Sarnelli A, Celli M, Fantini L, Moretti A, Galassi R, De Giorgi U, Paganelli G.

Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2189-2194. doi: 10.1007/s00259-017-3791-4. Epub 2017 Aug 11.

PMID:
28801787
46.
47.

Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis.

Necchi A, Mariani L, Lo Vullo S, Yu EY, Woods ME, Wong YN, Harshman LC, Alva A, Sternberg CN, Bamias A, Grivas P, Koshkin VS, Roghmann F, Dobruch J, Eigl BJ, Nappi L, Milowsky MI, Niegisch G, Pal SK, De Giorgi U, Recine F, Vaishampayan U, Berthold DD, Bowles DW, Baniel J, Theodore C, Ladoire S, Srinivas S, Agarwal N, Crabb S, Sridhar S, Golshayan AR, Ohlmann C, Xylinas E, Powles T, Rosenberg JE, Bellmunt J, van Rhijn B, Galsky MD, Hendricksen K; Young Academic Urologists-Urothelial Carcinoma Group-European Association of Urology and the Retrospective International Study of Invasive/Advanced Cancer of the Urothelium group.

Eur Urol Focus. 2017 Jun 3. pii: S2405-4569(17)30125-6. doi: 10.1016/j.euf.2017.05.006. [Epub ahead of print]

48.

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study.

Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD; Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).

Eur Urol Focus. 2018 Dec;4(6):937-945. doi: 10.1016/j.euf.2017.03.011. Epub 2017 Mar 31.

PMID:
28753879
49.

Real-life clinical practice results with vinflunine in patients with relapsed platinum-treated metastatic urothelial carcinoma: an Italian multicenter study (MOVIE-GOIRC 01-2014).

Passalacqua R, Lazzarelli S, Donini M, Montironi R, Tambaro R, De Giorgi U, Pignata S, Palumbo R, Ceresoli GL, Del Conte G, Tonini G, Morelli F, Nolè F, Panni S, Rondini E, Guida A, Zucali PA, Doni L, Iezzi E, Caminiti C.

BMC Cancer. 2017 Jul 19;17(1):493. doi: 10.1186/s12885-017-3466-3.

50.

Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.

Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G.

Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29.

PMID:
28572027

Supplemental Content

Loading ...
Support Center